The expression profile of functional regulatory T cells, CD4+CD25high+/forkhead box protein P3+, in patients with ulcerative colitis during active and quiescent disease
Authors:
Open Access
- 11 February 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 156 (2) , 320-327
Abstract
Regulatory T cells (Treg) have an essential role in maintaining immune tolerance in the gut. The functional CD4+ Treg express the transcription factor forkhead box protein 3 (FoxP3) or a CD25high in humans. Further, depletion of elevated granulocytes/monocytes by extracorporeal adsorption (GMA) induces immunomodulation in patients with ulcerative colitis (UC). We investigated the impact of GMA on Treg. Thirty-one UC patients, clinical activity index (CAI) 12·1 ± 2·97, refractory to conventional medications including intravenous corticosteroid and 13 healthy controls (HC), were included. Patients received five GMA sessions over 5 weeks. Biopsies from the rectal mucosa and blood samples at baseline and post-GMA were immunostained with anti-CD4/FoxP3 and anti-CD4/CD25 antibodies for immunohistochemistry and flow cytometry. Following GMA, 22 of 31 patients achieved remission (CAI ≤ 4, P < 0·01) and their endoscopic activity index decreased from 10·6 ± 2·32 to 4·75 ± 1·48 (P = 0·003). The circulating CD4+CD25high+ Treg level was low and increased markedly in responders (P < 0·02). In the nine non-responders, the baseline CD4+CD25high+ Treg level was about 50% of the level in the responders (P < 0·03) or in the HC (P < 0·01), and all nine had to undergo colectomy. Conversely, the number of CD4+/FoxP3+ mucosal Treg in GMA responders decreased significantly after the fifth GMA session compared with the baseline level (P < 0·05). It is believed that the CD4+ Treg has an essential role in the control of immune pathology in UC patients and a net influx of these cells from the circulation into the mucosa may proceed to suppress inflammation. GMA can impact the circulating as well as the mucosal levels of Treg.Keywords
This publication has 29 references indexed in Scilit:
- Basal lymphoid aggregates in ulcerative colitis colon: a site for regulatory T cell actionClinical and Experimental Immunology, 2008
- Inflammatory bowel diseases: A disease (s) of modern times? Is incidence still increasing?World Journal of Gastroenterology, 2008
- Demonstration of Low-Regulatory CD25High+CD4+ and High-Pro-inflammatory CD28−CD4+ T-Cell Subsets in Patients with Ulcerative Colitis: Modified by Selective Granulocyte and Monocyte Adsorption ApheresisDigestive Diseases and Sciences, 2007
- Clinical application of human CD4+CD25+regulatory Tcells for the treatment of inflammatory bowel diseasesExpert Opinion on Biological Therapy, 2005
- T cells that cannot respond to TGF-β escape control by CD4+CD25+ regulatory T cellsJournal of Experimental Medicine, 2005
- Adacolumn, an Adsorptive Carrier Based Granulocyte and MonocyteApheresis Device for the Treatment of Inflammatory and RefractoryDiseases Associated with LeukocytesTherapeutic Apheresis and Dialysis, 2003
- Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: A multicenter studyJournal of Clinical Apheresis, 2001
- Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid TherapyNew England Journal of Medicine, 1994
- Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.BMJ, 1989
- A Disquisition on Suppressor T CellsImmunological Reviews, 1975